David E Gerber Selected Research

Pancreatic Neoplasms (Pancreatic Cancer)

7/2017	Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
1/2017	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.
11/2015	Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.
1/2015	Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways.
6/2013	BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.
2/2008	Targeted therapies: a new generation of cancer treatments.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David E Gerber Research Topics

Disease

82	Neoplasms (Cancer) 01/2024 - 03/2006
57	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 12/2008
35	Lung Neoplasms (Lung Cancer) 01/2024 - 11/2009
12	Disease Progression 07/2022 - 12/2014
6	Pancreatic Neoplasms (Pancreatic Cancer) 07/2017 - 02/2008
5	Exanthema (Rash) 01/2024 - 02/2008
4	Autoimmune Diseases (Autoimmune Disease) 01/2023 - 11/2016
4	Brain Neoplasms (Brain Tumor) 01/2022 - 05/2007
3	Infections 11/2023 - 01/2023
3	Pneumonia (Pneumonitis) 01/2023 - 01/2017
3	Diarrhea 11/2022 - 10/2017
3	Nausea 11/2022 - 12/2015
3	Lymphoma (Lymphomas) 03/2022 - 05/2007
3	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 01/2007
3	Neoplasm Metastasis (Metastasis) 07/2021 - 01/2019
3	Adenocarcinoma 11/2020 - 08/2013
3	Necrosis 10/2018 - 11/2015
3	Glioma (Gliomas) 04/2007 - 01/2007
2	Melanoma (Melanoma, Malignant) 01/2023 - 01/2023
2	Myocarditis (Carditis) 01/2023 - 01/2020
2	Vomiting 11/2022 - 12/2015
2	Venous Thromboembolism 11/2022 - 08/2008
2	Mouth Neoplasms (Oral Cancer) 01/2021 - 11/2019
2	Carcinogenesis 01/2021 - 01/2017
2	Adenocarcinoma of Lung 10/2020 - 12/2015
2	Fatigue 01/2020 - 10/2017
2	Head and Neck Neoplasms (Head and Neck Cancer) 11/2015 - 03/2010
2	Hemorrhage 08/2014 - 08/2008
1	Hodgkin Disease (Hodgkin's Disease) 01/2024
1	Neutropenia 01/2024
1	Prostatic Neoplasms (Prostate Cancer) 01/2023
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2023
1	Hypertriglyceridemia 01/2023
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2023
1	Skin Diseases (Skin Disease) 01/2023

Drug/Important Bio-Agent (IBA)

24	Immune Checkpoint InhibitorsIBA 08/2023 - 01/2016
10	Biomarkers (Surrogate Marker)IBA 01/2024 - 11/2017
9	NivolumabIBA 01/2024 - 10/2015
7	Tyrosine Kinase InhibitorsIBA 03/2022 - 08/2011
7	Monoclonal AntibodiesIBA 01/2015 - 04/2007
6	PlatinumIBA 01/2023 - 03/2015
6	CytokinesIBA 03/2022 - 09/2010
6	ErbB Receptors (EGF Receptor)IBA 01/2022 - 12/2008
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 08/2011
5	AntibodiesIBA 11/2023 - 01/2019
5	Docetaxel (Taxotere)FDA Link 01/2023 - 10/2015
5	Carboplatin (JM8)FDA LinkGeneric 07/2022 - 08/2013
5	Pemetrexed (MTA)FDA Link 07/2022 - 09/2012
5	Cisplatin (Platino)FDA LinkGeneric 01/2017 - 09/2012
5	PhosphatidylserinesIBA 01/2016 - 08/2011
5	bavituximabIBA 01/2016 - 08/2011
4	LigandsIBA 01/2022 - 10/2015
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2010
4	Bevacizumab (Avastin)FDA Link 11/2020 - 09/2012
4	beta-lapachoneIBA 10/2018 - 11/2015
3	AutoantibodiesIBA 01/2024 - 01/2020
3	IpilimumabIBA 01/2024 - 01/2017
3	durvalumabIBA 12/2023 - 01/2020
3	pembrolizumabIBA 01/2023 - 01/2021
3	Circulating Tumor DNAIBA 03/2022 - 01/2021
3	brigatinibIBA 03/2022 - 02/2017
3	VaccinesIBA 11/2020 - 05/2013
3	AntigensIBA 11/2020 - 04/2007
3	Anaplastic Lymphoma KinaseIBA 03/2019 - 12/2015
3	NAD (NADH)IBA 01/2019 - 11/2015
3	Etoposide (VP 16)FDA LinkGeneric 01/2017 - 07/2015
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2017 - 11/2012
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2013 - 09/2012
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2023 - 03/2022
2	Messenger RNA (mRNA)IBA 10/2020 - 01/2014
2	CTLA-4 AntigenIBA 01/2020 - 01/2019
2	Temozolomide (Temodar)FDA LinkGeneric 12/2019 - 01/2007
2	CatalaseIBA 01/2019 - 07/2017
2	Adenosine Triphosphate (ATP)IBA 01/2019 - 11/2015
2	ARQ 197IBA 01/2018 - 08/2011
2	Oxidoreductases (Dehydrogenase)IBA 07/2017 - 11/2015
2	quinone (benzoquinone)IBA 07/2017 - 11/2015
2	Phosphotransferases (Kinase)IBA 01/2017 - 01/2017
2	olaratumabIBA 01/2017 - 11/2012
2	CrizotinibIBA 12/2015 - 02/2015
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2015 - 06/2013
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2013 - 09/2012
1	Epidermal Growth Factor (EGF)IBA 01/2024
1	Brentuximab VedotinIBA 01/2024
1	Complement System Proteins (Complement)IBA 01/2024
1	Iodide Peroxidase (Deiodinase)IBA 01/2023
1	FenretinideIBA 01/2023
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2023
1	bemcentinibIBA 01/2023
1	phospholipid emulsion soybean oil (Intralipid)IBA 01/2023
1	anti-thyroglobulinIBA 01/2023
1	AutoantigensIBA 01/2023

Therapy/Procedure

65	Therapeutics 01/2024 - 01/2007
29	Drug Therapy (Chemotherapy) 01/2024 - 02/2008
17	Immunotherapy 01/2024 - 05/2013
14	Radiotherapy 08/2023 - 01/2007
4	Maintenance Chemotherapy 01/2018 - 02/2011
2	Chemoradiotherapy 01/2022 - 11/2020
2	Precision Medicine 01/2017 - 12/2010
1	Castration 01/2023